PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for December 6, 2004 Subscribe to this News Feed    
 

Research And Markets - All Manufacturers Of Pharmaceutical Products, Biologics, Diagnostics And Devices Controlled By The FDA And Similar Overseas Authorities Are Subject To Facility Inspections, Both Before Approval Of A New Product And Routinely Thereafter

Research and Markets (researchandmarkets.com/reports/c10621) has announced the addition of A Guide to Good Manufacturing Practice, 2nd Edition to their offering.

(PRWEB) December 6, 2004 -- A Guide to Good Manufacturing Practices, 2nd Edition analyzes the contents of the latest versions of the GMP rules laid down by the USA, Canada and Japan, ICH, the EC and WHO. This Guide provides pharmaceutical and biological companies of all sizes with assistance in compliance with these rules. The Guide is addressed particularly to smaller sized companies, perhaps those with their first new drug, working on this extra challenge to their capabilities.

Research and Markets (http://www.researchandmarkets.com/reports/c10621) has announced the addition of A Guide to Good Manufacturing Practice, 2nd Edition to their offering.

The regulations and guidelines outlining GMP originated with the Food and Drug Administration (FDA) of the USA, and have been in operation in their current form since 1978. Other countries, including Canada, Japan, Australia, Switzerland and the members of the European Union, have published similar codes. The codes are empowered by national regulations.

Moves to harmonize these codes internationally have taken place, under ICH auspices. However, a recent review of the contents of the regulations from major players in the pharmaceutical industry concluded that there were far more similarities than differences in these rules. To this end, the ICH decided in the year 2000 that the only new GMP guidance that was needed was for the manufacturers of active pharmaceutical ingredients in bulk-the existing regulations for finished products were adequate.

The contents of this report are as follows:
Chapter 1: Executive Summary                                                                    
Chapter 2: Introduction                                                                                
Chapter 3: International Regulations Governing GMP                            
Chapter 4: Standard Operating Procedures                                            
Chapter 5: Validation of Procedures, Processes, and Methods            
Chapter 6: Critical Compliance Issues for Active Principal
Chapter 7: Critical Compliance Issues for Biologicals                            
Chapter 8: Preparation of ICH Manufacturing Documentation            
Chapter 9: Internal and External Inspections                                            
Chapter 10: Conclusions                                                                                
Chapter 11: References and Further Reading                                        
Chapter 12: Appendices                                                                                

TABLE OF EXHIBITS

For more information visit http://www.researchandmarkets.com/reports/c10621

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Laura Wood
RESEARCH AND MARKETS
35314100862
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.